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Ewing sarcoma (ES), an aggressive bone and soft‐tissue tumor, is treated with
chemotherapy, radiotherapy, and surgery. Intra‐operative distinction between healthy
and tumorous tissue is of paramount importance but challenging, especially after
chemotherapy and at complex anatomical locations. Near infrared (NIR) fluorescence‐
guided surgery (FGS) is able to facilitate the determination of tumor boundaries intra‐
operatively, improving complete resection and therefore survival. This review evaluates
potential ES‐specific proteins from the literature as targets for NIR FGS.
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1 | INTRODUCTION
Ewing sarcoma (ES) is a small, round cell sarcoma that shows
pathognomonic molecular findings, and varying degrees of neural
differentiation.1 ES is the second most common primary osseous
malignancy in children and young adults after osteosarcoma, with a
peak incidence in the second decade of life.2-4 Treatment generally
consists of chemotherapy followed by surgery and/or radiotherapy. This
multimodal approach drastically improved survival, from a 10‐year
overall survival of approximately 10% up to 55% to 65% in patients with
localized disease and 20% to 35% for patients with metastatic
disease.5-10 During the last few decades local treatment has changed
from routinely amputation to limb‐salvage, in which preservation of a
functioning limb is at the essence of achieving clear margins.7
ES arises from the diaphysis of long bones with early
involvement of the surrounding soft tissue. The soft tissue mass
is usually large, circumferential around the involved bone and
might even exceed the intra‐osseous component in size.1 Neoad-
juvant treatment causes shrinkage of both the bony and soft tissue
component, but tumor boundaries can still consist of vital tumor
cells. The infiltrative rather than pushing type of tumor outgrowth
of ES impedes border definition, but achieving wide surgical
resection is of paramount importance for survival in ES. Incom-
plete resection occurs in 20% to 30% of the cases.11-13 A large
study of 244 patients registered in the Cooperative Ewingʼs
Sarcoma Studies showed that the local recurrence rate in patients
with or without systemic metastasis was significantly lower after
wide resection compared to marginal or intralesional resection
(5% vs 12%).13 Another large study of 512 ES patients showed that
local control and 5‐year disease‐free survival are significantly
better when adequate surgical margins are achieved (96.6% vs
71.7% and 69.6% vs 46.3% respectively).12
Developments in intra‐operative imaging, like computer tomogra-
phy‐based systems, make accurate defining and localization of the
osseous margins possible. Magnetic resonance imaging enables
adequate pre‐operative visualization of soft tissue involvement and
can show possible ingrowth in nearby neurovascular tissue, which is
essential knowledge for surgical planning. However the intra‐operative
definition of soft tissue margins remains challenging, especially after
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neoadjuvant treatment.7,14,15 During surgery the surgeon relies mostly
on his eyes and hands when distinguishing tumor issue margins.
Furthermore, about 50% of the Ewing sarcoma’s arise in the axial
skeleton with the pelvic and spine as common locations. Accurate
surgery with clear margins is challenging in these complex anatomical
locations.5 This emphasizes the need for tools to define surgical
margins of soft tissue involvement during surgery.
Targeted imaging uses membrane proteins that are over‐expressed
on tumor or tumor‐associated cells to visualize tumors. One of the
most eye‐catching technologies in targeted imaging is near infrared
(NIR) fluorescence imaging. It provides optical contrast between tumor
and surrounding healthy tissue in a broad range of (pre)clinical tumor
types and might have the potential to delineate soft tissue involve-
ment of ES during surgery. NIR light is less absorbed than visible light
and thus penetrates tissue much deeper. Furthermore, lower auto‐
fluorescence is observed at NIR wavelengths which enables good
contrast. Because NIR light is invisible for humans, the surgical field
remains unstained, but a dedicated NIRF camera system and screen
are needed for visualization.16-19
Over the past 10 years, clinical research has focused mainly on non‐
specific fluorescent agents like indocyanine green (ICG), which are
primarily used for vascular imaging and sentinel lymph node proce-
dures.20 Unfortunately these simple non‐targeted dyes are not useful to
target malignant cells. Therefore, many oncologic targets have been
explored and indeed sub‐millimeter sized tumor nodules could be
detected in animal models.21 With the first tumor‐targeting clinical trial
performed in 2011 by van Dam et al,22 fluorescence guided surgery
(FGS) is at the doorstep of clinical translation to oncologic surgery, and
many targets are being explored using numerous detection platforms
like antibodies, peptides, and RNA aptamers.23
So far, NIR‐based FGS has not been used to define margins in ES.
Finding a good target might be challenging because of its uniqueness
and the limited similarities with other tumor types. Sand et al24 studied
membranous CXCR4 expression on ES cell lines using a fluorescently
labeled CXCR4 targeting peptide. They showed that the fluorescently
tagged CXCR4 targeting peptide was able to detect CXCR4 on living ES
cells. Nevertheless, data are not explored in vivo yet.
When defining a potential biomarker for targeting, the following
characteristics are of utmost importance: extracellular biomarker
localization, expression pattern, tumor‐to‐healthy tissue ratio, the
percentage of positive tumors, reported successful use of the
biomarker in in vivo imaging studies and internalization.23,25
The aim of this study was to provide an overview of possible
tumor‐specific biomarkers in ES. For this purpose, a systematic
analysis of scientific literature was conducted, using the recently
published ES surfaceome database, based on three ES cell lines
(A673, TC‐32, and TTC‐466) as a reference.26
2 | MATERIALS AND METHODS
This study was performed according to the Preferred Reporting
Items for Systematic Reviews and Meta‐analyses guidelines.27 The
review protocol for this study was prospectively registered at
PROSPERO* (registration number CRD42017080720).
2.1 | Search strategy
A search strategy was developed, and searches were run in the
following databases in October 2017: PubMed, Embase, Cochrane
Library, Academic Search Premier and Web of Science. Search
strategies for all databases were adapted from the PubMed strategy.
The search strategy consisted of the keywords “Ewing sarcoma,”
“biomarker,” “target” and abbreviations thereof. See Supporting
Information file 1 for the complete search strategies for each
database.
2.2 | Eligibility criteria
Multiple study designs were considered for this review, including
clinical trials (phase I, II, and III) and prospective or retrospective
cohort studies. Animal studies, case reports, reviews, viewpoints, or
conference reports were excluded. We searched for systematic
reviews on this topic and only included original articles in our review.
Studies were eligible for inclusion if they met the following criteria:
(1) Report of cell surface protein expression in the primary ES tumor;
(2) Cell surface protein expression was evaluated by flow cytometry,
Western blot or immunohistochemistry; (3) Positive expression in
50% or more of the ES samples tested; (4) Study was published in the
English language. The eligibility of the studies was assessed by two
authors (SB and PD). Disagreements were resolved by discussion
during a consensus meeting. Persistent disagreements were settled
by consultation of a third reviewer (PH).
2.3 | Data extraction
The following data were extracted from eligible studies: target
characteristics, sample size, type of sample, percentage of positive ES
samples and pattern of expression.
2.4 | Target selection: scoring system
Considerations to select the optimal target for tumor imaging are: (1)
The location and accessibility of the target on the cell membrane; (2)
Upregulation on tumor cells compared to cells in adjacent normal
tissue. Note that targets/biomarkers like FLI1 and NKX2.2, which are
considered standards for ES in diagnostics and pathology, cannot be
used for in vivo imaging, because of nuclear or cytoplasmic
expression.28-32
To select the best biomarkers useful for NIR FGS in ES, we
developed a scoring system based on the Target Selection Criteria
(TASC) of van Oosten et al25 to classify the targets based on their
*http://www.crd.york.ac.uk/prospero.
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characteristics and the evidence from the literature search (Table 1).
The scoring system is based on five domains:
I) Number of samples tested. This provides a measurement of the
evidence from the literature search.
II) Pattern of expression. This concerns the expression pattern
evaluated in the single tissue samples tested. In the most ideal
situation a target is expressed by all tumor cells, but, in reality,
intra‐tumoral heterogeneity is more likely. When a target is
equally distributed through the tumor tissue, resulting in a
strong diffuse pattern of expression, the target is more
applicable for imaging than when it shows a focal expression.
The intensity of the expression pattern was defined as + for mild
expression (5% to 20% of cells in one sample positive), ++ for
moderate expression (25% to 50% of cells in one sample
positive) and +++ for strong expression (>50% of cells in one
sample positive).
III) Upregulation in ES. To assess this we used the recently
published ES surfaceome database of Town et al,33 based on
three ES cell lines (A673, TC‐32, and TTC‐466). They used
next‐generation RNA sequencing and coupled this to a
database of known genes encoding for cell surface proteins
(the surfaceome) to define a cell surface proteome of ES
compared with mesenchymal stem cells (MSC). A large list of
genes encoding for cell surface proteins was created ordered
by differences in expression level between ES and MSC. The
first 1000 genes on this list show a very high upregulation in
ES compared to MSC. From place 5000 onwards genes show a
small increase in ES compared to MSC or even higher levels in
MSC than in ES. Obviously, enhanced RNA expression does
not consequently mean protein upregulation.
IV) Percentage of tested ES samples that showed expression. The
percentage is presented as a mean together with the range.
V) Previously imaged: if a target is previously used for in vivo
targeted imaging (either pre‐clinical or in PET/SPECT studies) it
indicates that a target is suitable for imaging purposes.
The maximum score for a target is 10 points. We chose 7 points
as the cut‐off value for potentially suitable targets for targeted
imaging in ES.
3 | RESULTS
3.1 | Study selection
The initial search strategy identified 4943 records (PubMed n =2203;
Embase n=1585; Web of Science n=1054; Cochrane Library n =19;
Academic Search Premier n=82). After removal of 2128 duplicates,
2815 records were available for screening. After screening of the titles
and abstracts, 197 full‐text articles were obtained, of which 111
eventually did not meet the eligibility criteria: 83 studies did not report
cell surface expression, 12 studies reported expression levels <50%, 13
studies were not about cell surface expression in ES, two studies were
not about expression in primary ES tumors and of one study no full text
was available. In total 86 studies were included studying 47 biomarkers
(Figure 1). The reviewers initially disagreed on 21 inclusions during the
selection process, but eventually a consensus was reached for all studies.
3.2 | Study characteristics
The characteristics of the 47 included biomarkers are presented in
Supporting Information file 2.
3.3 | Candidate proteins for targeted imaging
The target scoring system (Table 1) was applied to the 47 targets listed in
appendix II. Nine targets scored seven points or higher. Table 2 provides
an overview of the nine targets that are candidates for near infra-red
fluorescence guided surgery (NIR FGS) in ES. Targets are subdivided into
receptors and cell adhesion molecules (CAM) or anchoring proteins. The
following nine targets are considered potentially suitable (Table 2): CD99,
LINGO‐1, IGF‐1R, C‐kit, NOTCH receptor, CXCR4, NPY receptor Y1,




CD99 (also called MIC2, O13 or T‐cell surface glycoprotein E2) is a
transmembrane glycoprotein encoded by the CD99/MIC2X gene. CD99
is involved in the differentiation of primitive neuroectodermal cells,
TABLE 1 Targets scoring system
Target scoring system 0 1 2
I Sample size 0‐9 10‐50 >50
II Pattern of expression Focal Diffuse, mild or heterogenic Diffuse, moderate or strong (++/+++)
III Upregulation (based on the surfaceome of Town et al) ≥5000 1000‐5000 <1000
IV Percentage expression 50% to 69% 70% to 85% >85%
V Previously imaged No Yes
Eligible biomarkers were granted points (0, 1, or 2) based on five domains: (I) sample size; (II) expression pattern, which comprises the intensity of the
expression of the target; (III) upregulation compared to healthy tissue, using the recently published ES surfaceome database of Town et al33; (IV)
percentage positive cells; (V) previously imaged. The maximum score is 10. Targets that score 7 or higher are potentially suitable for targeted imaging.
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migration of leukocytes, and apoptosis of T cells. It may promote growth
and migration of tumor cells by downregulation of the potassium
channel modulatory factor, KCMF1, which is thought to be a metastasis
suppressor gene.34 Overexpression of CD99 has been found in
lymphoblastic lymphoma, rhabdomyosarcoma, synovial sarcoma, me-
senchymal chondrosarcoma, and the blastemal component of Wilms
tumor. CD99 expression in ES is strong to moderate, diffuse and
membranous and present in approximately 96% of ES tumors. 30, 34‐60
The expression level is much higher in ES compared with MSC.33 A
preclinical study using 64Cu labeled mouse monoclonal antibody against
CD99 detected primary ES tumors and metastases with higher
sensitivity than conventional FDG‐PET in vitro as well as in xenograft
mouse models.35 Based on this study CD99‐targeted FGS seems
feasible, preferably using human or humanized antibodies to avoid
human anti‐mouse induced complications. Human CD99 antibody scFv‐
fragments have recently been developed using a synthetic phage
antibody library.36 Although intended for therapy, the specificity of
these anti‐CD99 scFv fragments for ES, in combination with the small
size of these fragments in comparison with full‐size antibodies (27 vs
150 kDa), might offer an excellent agent for FGS of ES.
CXCR4
CXCR4 (CD184) is the receptor for chemokine SDF‐1/CXCL12.
CXCR4/SDF‐1 signaling plays a role in chemotaxis of hematopoietic
cells and in neuron generation during embryogenesis and adult life. It
is absent in most healthy tissues but upregulated in the tumor
microenvironment of many tumor types, where it is associated with
metastasis, angiogenesis, and tumor growth.24 Also in ES CXCR4 is
associated with tumor progression and metastasis.37-39 Overall 82%
of ES tumors are positive for CXCR4 (range 64% to 100%), with
cytoplasmic and membranous staining varying from weak to
strong.24,38 A surfaceome study of ES by Town et al33 showed no
expression of CXCR4 in MSC, which makes CXCR4 an attractive
target for targeted imaging. Sand et al24 studied membranous CXCR4
expression in ES cell lines using a fluorescently labeled CXCR4
targeting peptide (MSAP‐Ac‐TZ14011), indicating the feasibility of
this agent for FGS. The first in human experience with a radiolabeled
version of a similar peptide (Pentixafor) in a small and heterogeneous
patient cohort did not completely fulfill the expectations in
comparison with standard (18)F‐FDG PET.40
NPY receptor Y1
Neuropeptide Y (NPY) receptors are members of the G‐protein
coupled receptor superfamily. The NPY receptor Y1 is expressed in
the central nervous system and periphery including heart, kidney, and
gastro‐intestinal tract. It mediates the function of a neurotransmitter
NPY, and a gastrointestinal hormone peptide YY (PYY). Activation is
associated with modulation of the MAPK pathway, which leads to
increased or uncontrolled cell proliferation and resistance to
apoptosis.41 NPY receptor Y1 is highly expressed in human cancers,
for instance, breast cancer. Körner et al42 studied NPY expression in
several sarcomas, including ES. ES samples showed a strikingly high
F IGURE 1 Flowchart study selection
process
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NPY receptor Y1 expression. 84% of the tumors tested positive with
high receptor density. Recently Li et al43 developed fluorescent
nanobubbles (NBs) for specific targeting of Y1 receptors over-
expressed in breast cancer. The fluorescent NBs were used as
ultrasound contrast agents for targeted molecular imaging with
contrast‐enhanced ultrasound and fluorescent imaging using the
Lumina XRMS system. The NBs showed high affinity and specificity
for NPY receptor Y1, providing evidence that specific targeted imaging
might also be applicable in ES.
LINGO1
Leucine‐rich repeat and immunoglobulin domain containing pro-
tein 1 (LINGO1) is a functional component of the Nogo receptor. It
plays a key role in the central nervous system where it is an
important negative regulator of oligodendrocyte differentiation
and axonal myelination.44,45 It is characterized by a large and well
defined extracellular domain.46 Town et al33 explored the cell
surface proteome of ES and found that LINGO1 is highly
expressed in 91% of ES and not in any other somatic tissue apart
from the brain, suggesting it as an appropriate candidate for
imaging. The human monoclonal antibody Opicinumab (Li81,
BIIB033), has recently been developed to block LINGO1 as a
treatment of multiple sclerosis. Li81 was isolated using Fab phage
display technology and engineered into a human IgG1 mono-clonal
lonal antibody with high affinity and specificity to LINGO1.47,48
Initial clinical trials showed disappointing results, but regardless of
its therapeutic efficiency this monoclonal antibody could in
principle be applied for use of FGS in ES.
IGF‐1R
Insulin‐like growth factor 1 receptor (IGF‐1R), a tyrosine kinase
receptor, is found on the surface of many human cells. It is
activated by IGF‐1 or IGF‐2, playing a role in transformation
events like hypertrophy of skeletal muscles and other tissues. IGF‐
1R is upregulated in various types of tumors, including bladder,
breast, prostate and lung cancer. IGF‐1R signaling is thought to be
play a role in survival and cell growth of cancer cells. It induces an
anti‐apoptotic effect, allowing cancer cells to resist the cytotoxic
properties of chemotherapeutic drugs or radiotherapy.49-53 IGF‐
1R is expressed in 78% of the ESs, but it shows to be very variable
(range 33% and 100%). The pattern of expression is often diffuse,
varying from weak to strong.49-53 Several pre‐clinical studies
evaluated the use of IGF‐1R antibody‐conjugated fluorophores to
identify tumor cells in animal models of various cancer types.
TABLE 2 Potentially suitable targets for NIR FGS in Ewing sarcoma
Target Function Score
Receptors
CD99 (MIC2, O13 or T‐cell
surface glycoprotein E2)
Cell surface glycoprotein involved in differentiation of primitive neuroectodermal cells,
apoptosis of T cells, T cell adhesion, migration of leukocytes; may promote growth and
migration of tumor cells.
10
CXCR4 Receptor for chemokine SDF‐1/CXCL12, which is involved in chemotaxis of hematopoietic
cells and neuron generation. In cancer is plays a role in the tumor microenvironment, where
it is associated with metastasis, angiogenesis and tumor growth.
9
NPY‐R‐Y1 Expressed in the central nerve system and periphery (heart, kidney, gastro‐intestinal tract);
activation is associated with modulation of the MAPK pathway, which leads to increased or
uncontrolled cell proliferation and resistance to apoptosis.
8
LINGO‐1 Functional component of Nogo receptor signaling complex. Important negative regulator of
oligodendrocyte differentiation and axonal myelination.
8
IGF‐1R A tyrosine kinase receptor (TKR) that is activated by insulin‐like growth factor 1 (IGF‐1) and
involved in hypertrophy of skeletal muscles and other tissues and cell survival; shows anti‐
apoptotic effects that allow cancer cells to resist the cytotoxic properties of
chemotherapeutic drugs or radiotherapy.
8
C‐kit (CD117) Stem cell factor receptor that is important for development and survival of mast cells,
hematopoietic stem cells, melanocytes, germ cells and interstitial cells of Cajal; plays role in
cancer cell survival, proliferation and differentiation.
7
NOTCH‐R Involved in cell signaling; shows oncogenetic (suppress apoptosis; promote neo‐angiogenesis,
tumor cell growth and metastasis) and tumor‐suppressive (inhibit angiogenesis and induced
cell differentiation or apoptosis) functions.
7
CAM/anchoring proteins
Occludin Integral plasma‐membrane protein that is required for cytokine‐induced regulation and
formation of the tight junction paracellular permeability barrier; in cancer it attributes to
increased invasion and reduced adhesion which promotes metastasis.
9
Claudin‐1 Tight junction protein that contributes in cell‐to‐cell adhesion by forming continuous seals
around cells; dysregulation of claudins plays a role in tumorigenesis, the exact underlying
mechanism remains unclear.
8
Abbreviations: CAM, cell adhesion molecules; FGS, fluorescence guided surgery; NIR, near infrared.
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Zhang et al54 used the humanized monoclonal antibody AVE‐1642
conjugated to Alexa 680 to target xenograft tumor and was able to
detect IGF1R down regulation, with little nonspecific targeting of
other tissues or organs in mice. Park et al55 used IGF‐1R
antibodies conjugated with PEG‐ylated 650 nm fluorophores to
selectively highlight liver metastases in a liver metastasis model of
colon cancer in nude mice. The IGF‐1R targeted fluorophore‐
antibody conjugation enabled clear imaging of liver metastases
compared to normal liver tissue, despite the relatively high
expression level in normal liver tissue. Humanized anti‐IGF‐1R
monoclonal antibodies, like AVE1642 and R1507, have been
developed for therapy. These antibodies have been evaluated for
radiolabel‐based SPECT/PET as well, but only in pre‐clinical
settings.56,57
C‐kit (CD117)
C‐kit is a tyrosine kinase receptor important for development and
survival of mast cells, hematopoietic stem cells, melanocytes, germ
cells and interstitial cells of Cajal. It plays a role in tumor growth
and progression.58 C‐kit is expressed by the KIT gene which is
highly upregulated in ES cell‐lines.33 The intensity of the expres-
sion varies however and only 60% of ES show a strong
membranous expression (range 31% to 100%). Staining intensity
varies from weak to strong and is diffuse membranous and/or
cytoplasmic.59 Metildi et al60 used fluorescently labeled (Alexa-
Fluor 488) rat‐derived anti‐KIT antibodies to label KIT‐expressing
Gastrointestinal Stromal Tumors (GISTs) in vivo and laparoscopi-
cally. They provided proof of concept and confirmed that KIT could
be accurately labeled in GISTs for detection of primary tumors, as
well as for detection of small metastatic deposits that might be
missed at the time of surgical resection. The recently developed
humanized monoclonal antibody KTN0158 is being evaluated in
dogs for therapeutic purposes and might eventually have potential
for imaging.61
NOTCH receptor
NOTCH receptors 1‐4 are membranous proteins that play a role in
the development of numerous cells and tissue types. Their role in
cancer is ambiguous: They can act oncogenic or tumor‐suppressive,
dysregulating apoptosis, angiogenesis, tumor cell growth and
metastasis.62,63 Bennani‐Baiti et al64 investigated the expression of
NOTCH receptors in ES and found that NOTCH receptors are highly
expressed but do not appear to be active. 97% of the samples
showed positive staining for at least one NOTCH receptor and 75%
of the ESFT expressed two or more NOTCH receptors. The stainings
showed to be diffuse and only moderate membranous. The genes
encoding for the 4 different types of NOTCH receptors are
expressed slightly higher in ES compared to healthy tissue.33
Although potential therapeutic antibodies like bronctictuzumab
against activated NOTCH1 are being evaluated for therapy in
patient‐derived xenografts. Direct imaging of NOTCH has not been
described yet.
3.3.2 | CAMs or anchoring proteins
CAMs are membrane‐bound proteins that affect cellular processes.
Generally they are transmembrane receptors that consist of three
parts: an intracellular domain interacting with the cytoskeleton, a
transmembrane domain and an extracellular domain that interact
with either other CAMs or with the extracellular matrix. CAMs form
a large and diverse group of proteins, and most of the members
belong to either the immunoglobulin superfamily, or to the families of
integrins, cadherins or selectins.23,65
Claudin‐1
Claudin‐1, encoded by the CLDN1 gene, is a tight junction protein and
contributes to cell‐to‐cell adhesion by forming continuous seals around
cells, serving as a physical barrier to prevent solutes and water from
passing freely through the para‐cellular space.66,67 Abberant claudin
expression has been reported in several cancer types, including lung,
prostate and gastro‐intestinal tumors. Reduced claudin expression
results in loss of cell‐to‐cell adhesion and enhances cell motility, invasion
and metastasis. Abnormally high levels are also associated with
neoplastic growth. Schuetz et al66 studied the expression of claudin‐1
in 30 ES tissue samples and found expression in 63% of the samples.
Positive cases showed expression in more than 50% of the cells. In a
similar study Machado et al67 found a strong positive staining of
claudin‐1 in 285 of 415 tissue samples (76%). Rabinsky et al68
performed a study on real‐time NIR fluorescence endoscopic imaging
of mice bearing human colonic adenomas. They used a phage display‐
derived peptide CLDN‐1(53‐80) labeled with near‐infrared dye Cy5.5 at
the C‐terminus. After intra‐rectal administration they found a sig-
nificantly higher signal‐to‐background ratio for human colonic adeno-
mas compared to the signal‐to‐background ratio of normal in vivo
images. Alternatively, humanized monoclonal antibodies against
claudin‐1 are currently being evaluated for therapy, that could also be
explored for imaging purposes.69
Occludin
Occludin is an integral plasma‐membrane protein that is required for
cytokine‐induced regulation and formation of the tight junction para‐
cellular permeability barrier. Occludin is able to induce adhesion
when cells lack tight junctions.67 Although OCLN, the gene encoding
occludin is often downregulated in cancers. It is highly upregulated in
ES.33 Machado et al67 studied the expression of several epithelial
CAMs in ES, including occludin. Occludin showed a moderate to
strong, diffuse membranous staining in 287 out of 415 ES tissue
samples (76%). Because occludin is actually downregulated in many
tumors, there are currently no occludin targeting agents developed
for therapy or imaging.
4 | DISCUSSION
In this systematic review, we provide an overview of tumor‐specific
biomarkers that could be used for NIR fluorescence guided surgery in
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ES. Based on a scoring system, nine potentially suitable biomarkers
for targeted imaging were identified.
This study has several limitations. The studies evaluated in this
systematic review are heterogenic in the evaluation of cell surface
expression. Flow cytometry, Western blot analysis, immunohisto-
chemistry or a combination of these techniques are used. Further-
more, some targets like C‐kit and IGF‐1R show a wide range in
expression levels among studies whereas several other targets are
only investigated in a single study. Also the expression of a target
may depend on tumor stage. CXCR4, for example, is associated with
more advanced disease.38 The results of the studies evaluated might
therefore be less comparable. Finally, we used the recently published
surfaceome database in our scoring system to evaluate the
upregulation of a potential target in ES. This surfaceome is based
on three ES cell lines (A673, TC‐32, and TTC‐466).33 Serial passage of
cell lines can cause genotypic and phenotypic variation over an
extended period of time. Cell lines might therefor not adequately
reflect the true ES surfaceome.
The scoring system used in this review is a guidance tool that helped
in selecting potential targets. We chose a score of 7 as the cut‐off point
to identify potential targets. Other factors play a role in selecting the
most optimal candidate, such as toxicity of an antibody, the availability
of a humanized antibody and results from previous studies.
Following this study, immunohistochemical analysis and cell line‐
based validation of the potential biomarkers should be performed.
Next, imaging of a peptide or an antibody (derivative) conjugated to a
fluorophore should be assessed in vitro. Finally, if a target still shows
potential, in vivo testing with a specific binding ligand in a tumor
mouse model is needed.
5 | CONCLUSION
In ES a large number of tumor‐specific biomarkers is upregulated.
With the use of a scoring system, we identified CD99, LINGO‐1,
C‐kit, NOTCH receptor, CxCR4, NPY receptor Y1, Claudin‐1 and
Occludin as the most interesting ES specific biomarkers for the
use in NIR fluorescence guided surgery. Further immunohisto-
chemical and cell line‐based research of these potential targets
should be performed to elucidate the most optimal candidate.
With this study, the first steps are made to explore this promising
technique that is on the doorstep of optimizing orthopedic
oncologic surgery.
ACKNOWLEDGMENT
This study was supported by the Team Westland foundation.
REFERENCES
1. Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F. WHO
Classification of Tumours of Soft Tissue and Bone. 4th ed. Lyon, France:
IARC Press; 2013.
2. Damron TA, Ward WG, Stewart A. Osteosarcoma, chondrosarcoma,
and Ewing’s sarcoma: National Cancer Data Base Report. Clin Orthop
Relat Res. 2007;459:40‐47.
3. Esiashvili N, Goodman M, Marcus RB, Jr. Changes in incidence and
survival of Ewing sarcoma patients over the past 3 decades:
Surveillance Epidemiology and End Results data. J Pediatr Hematol
Oncol. 2008;30(6):425‐430.
4. van den Berg H, Kroon HM, Slaar A, Hogendoorn P. Incidence of
biopsy‐proven bone tumors in children: a report based on the Dutch
pathology registration “PALGA”. J Pediatr Orthop. 2008;28(1):29‐35.
5. Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in
Ewing’s tumor of bone: analysis of 975 patients from the European
Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol.
2000;18(17):3108‐3114.
6. Biswas B, Rastogi S, Khan SA, et al. Hypoalbuminaemia is an
independent predictor of poor outcome in metastatic Ewing’s
sarcoma family of tumours: a single institutional experience of 150
cases treated with uniform chemotherapy protocol. Clin Oncol (R Coll
Radiol). 2014;26(11):722‐729.
7. Abed R, Grimer R. Surgical modalities in the treatment of bone
sarcoma in children. Cancer Treat Rev. 2010;36(4):342‐347.
8. Ahrens S, Hoffmann C, Jabar S, et al. Evaluation of prognostic factors
in a tumor volume‐adapted treatment strategy for localized Ewing
sarcoma of bone: the CESS 86 experience. Cooperative Ewing
Sarcoma Study. Med Pediatr Oncol. 1999;32(3):186‐195.
9. Gaspar N, Hawkins DS, Dirksen U, et al. Ewing sarcoma: current
management and future approaches through collaboration. J Clin
Oncol. 2015;33(27):3036‐3046.
10. Werier J, Yao X, Caudrelier JM, et al. A systematic review of optimal
treatment strategies for localized Ewing’s sarcoma of bone after neo‐
adjuvant chemotherapy. Surg Oncol. 2016;25(1):16‐23.
11. Foulon S, Brennan B, Gaspar N, et al. Can postoperative radiotherapy
be omitted in localised standard‐risk Ewing sarcoma? An observa-
tional study of the Euro‐E.W.I.N.G group. Eur J Cancer. 2016;61:
128‐136.
12. Bacci G, Longhi A, Briccoli A, Bertoni F, Versari M, Picci P. The role of
surgical margins in treatment of Ewing’s sarcoma family tumors:
experience of a single institution with 512 patients treated with
adjuvant and neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys.
2006;65(3):766‐772.
13. Ozaki T, Hillmann A, Hoffmann C, et al. Significance of surgical
margin on the prognosis of patients with Ewing's sarcoma. A report
from the Cooperative Ewing's Sarcoma Study. Cancer. 1996;78
(4):892‐900.
14. Bölling T, Hardes J, Dirksen U. Management of bone tumours in
paediatric oncology. Clin Oncol (R Coll Radiol). 2013;25(1):19‐26.
15. Biswas B, Bakhshi S. Management of Ewing sarcoma family of tumors:
current scenario and unmet need.World J Orthop. 2016;7(9):527‐538.
16. Keereweer S, van Driel PBAA, Snoeks TJA, et al. Optical image‐
guided cancer surgery: challenges and limitations. Clin Cancer Res.
2013;19(14):3745‐3754.
17. Nguyen QT, Tsien RY. Fluorescence‐guided surgery with live
molecular navigation‐a new cutting edge. Nat Rev Cancer. 2013;13
(9):653‐662.
18. Bu L, Shen B, Cheng Z. Fluorescent imaging of cancerous tissues for
targeted surgery. Adv Drug Deliv Rev. 2014;76:21‐38.
19. Vahrmeijer AL, Hutteman M, van der Vorst JR, van de Velde CJH,
Frangioni JV. Image‐guided cancer surgery using near‐infrared
fluorescence. Nat Rev Clin Oncol. 2013;10(9):507‐518.
20. Alander JT, Kaartinen I, Laakso A, et al. A review of indocyanine
green fluorescent imaging in surgery. Int J Biomed Imaging. 2012;
2012:940585‐26.
21. Warram JM, de Boer E, Moore LS, et al. A ratiometric threshold for
determining presence of cancer during fluorescence‐guided surgery.
J Surg Oncol. 2015;112(1):2‐8.
912 | BOSMA ET AL.
22. van Dam GM, Themelis G, Crane LMA, et al. Intraoperative tumor‐
specific fluorescence imaging in ovarian cancer by folate receptor‐alpha
targeting: first in‐human results. Nat Med. 2011;17(10):1315‐1319.
23. Boonstra MC, de Geus SWL, Prevoo HAJM, et al. Selecting targets for
tumor imaging: an overview of cancer‐associated membrane proteins.
Biomark Cancer. 2016;8:119‐133.
24. Sand LGL, Buckle T, van Leeuwen FWB, et al. Fluorescent CXCR4
targeting peptide as alternative for antibody staining in Ewing
sarcoma. BMC Cancer. 2017;17(1):383.
25. van Oosten M, Crane LMA, Bart J, van Leeuwen FW, van Dam GM.
Selecting potential targetable biomarkers for imaging purposes in
colorectal cancer using TArget Selection Criteria (TASC): a novel
target identification tool. Transl Oncol. 2011;4(2):71‐82.
26. Town J, Pais H, Harrison S, et al. Exploring the surfaceome of Ewing
sarcoma identifies a new and unique therapeutic target. Proc Natl
Acad Sci U S A. 2016;113(13):3603‐3608.
27. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items
for systematic reviews and meta‐analyses: the PRISMA statement.
J Clin Epidemiol. 2009;62(10):1006‐1012.
28. Tawbi HA, Burgess M, Bolejack V, et al. Pembrolizumab in advanced
soft‐tissue sarcoma and bone sarcoma (SARC028): a multicentre,
two‐cohort, single‐arm, open‐label, phase 2 trial. Lancet Oncol.
2017;18(11):1493‐1501.
29. Hung YP, Fletcher CDM, Hornick JL. Evaluation of NKX2‐2
expression in round cell sarcomas and other tumors with EWSR1
rearrangement: imperfect specificity for Ewing sarcoma. Mod Pathol.
2016;29(4):370‐380.
30. McCuiston A, Bishop JA. Usefulness of NKX2.2 immunohistochem-
istry for distinguishing Ewing sarcoma from other sinonasal small
round blue cell tumors. Head Neck Pathol. 2017;12:89‐94.
31. Shibuya R, Matsuyama A, Nakamoto M, Shiba E, Kasai T, Hisaoka M.
The combination of CD99 and NKX2.2, a transcriptional target of
EWSR1‐FLI1, is highly specific for the diagnosis of Ewing sarcoma.
Virchows Arch. 2014;465(5):599‐605.
32. Yoshida A, Sekine S, Tsuta K, Fukayama M, Furuta K, Tsuda H.
NKX2.2 is a useful immunohistochemical marker for Ewing sarcoma.
Am J Surg Pathol. 2012;36(7):993‐999.
33. Town J, Pais H, Harrison S, et al. Exploring the surfaceome of Ewing
sarcoma identifies a new and unique therapeutic target. Proc Natl
Acad Sci U S A. 2016;113(13):3603‐3608.
34. Kreppel M, Aryee DNT, Schaefer K, et al. Suppression of KCMF1 by
constitutive high CD99 expression is involved in the migratory ability
of Ewing's sarcoma cells. Oncogene. 2006;25(19):2795‐2800.
35. O'Neill AF, Dearling JLJ, Wang Y, et al. Targeted imaging of Ewing
sarcoma in preclinical models using a 64Cu‐labeled anti‐CD99
antibody. Clin Cancer Res. 2014;20(3):678‐687.
36. Gellini M, Ascione A, Flego M, et al. Generation of human single‐chain
antibody to the CD99 cell surface determinant specifically recogniz-
ing Ewing’s sarcoma tumor cells. Curr Pharm Biotechnol. 2013;14
(4):449‐463.
37. Bennani‐Baiti IM, Cooper A, Lawlor ER, et al. Intercohort gene
expression co‐analysis reveals chemokine receptors as prognostic
indicators in Ewing’s sarcoma. Clin Cancer Res. 2010;16(14):
3769‐3778.
38. Berghuis D, Schilham MW, Santos SJ, et al. The CXCR4‐CXCL12 axis
in Ewing sarcoma: promotion of tumor growth rather than metastatic
disease. Clin Sarcoma Res. 2012;2(1):24.
39. Sand L, Szuhai K, Hogendoorn P. Sequencing overview of Ewing
sarcoma: a journey across genomic, epigenomic and transcriptomic
landscapes. Int J Mol Sci. 2015;16(7):16176‐16215.
40. Vag T, Gerngross C, Herhaus P, et al. First experience with
chemokine receptor CXCR4‐targeted PET imaging of patients with
solid cancers. J Nucl Med. 2016;57(5):741‐746.
41. Körner M, Reubi JC. NPY receptors in human cancer: a review of
current knowledge. Peptides. 2007;28(2):419‐425.
42. Korner M, Waser B, Reubi JC. High expression of neuropeptide Y1
receptors in ewing sarcoma tumors. Clin Cancer Res. 2008;14
(16):5043‐5049.
43. Li J, Tian Y, Shan D, et al. Neuropeptide Y Y1 receptor‐mediated
biodegradable photoluminescent nanobubbles as ultrasound contrast
agents for targeted breast cancer imaging. Biomaterials. 2017;116:
106‐117.
44. Mi S, Miller RH, Lee X, et al. LINGO‐1 negatively regulates
myelination by oligodendrocytes. Nat Neurosci. 2005;8(6):
745‐751.
45. Mi S, Lee X, Shao Z, et al. LINGO‐1 is a component of the Nogo‐66
receptor/p75 signaling complex. Nat Neurosci. 2004;7(3):
221‐228.
46. Mosyak L, Wood A, Dwyer B, et al. The structure of the Lingo‐1
ectodomain, a module implicated in central nervous system repair
inhibition. J Biol Chem. 2006;281(47):36378‐36390.
47. Pepinsky RB, Arndt JW, Quan C, et al. Structure of the LINGO‐1‐anti‐
LINGO‐1 Li81 antibody complex provides insights into the biology of
LINGO‐1 and the mechanism of action of the antibody therapy.
J Pharmacol Exp Ther. 2014;350(1):110‐123.
48. Mi S, Blake Pepinsky R, Cadavid D. Blocking LINGO‐1 as a therapy to
promote CNS repair: from concept to the clinic. CNS Drugs. 2013;
27(7):493‐503.
49. Scotlandi K, Benini S, Sarti M, et al. Insulin‐like growth factor I
receptor‐mediated circuit in Ewing's sarcoma/peripheral neuroecto-
dermal tumor: a possible therapeutic target. Cancer Res. 1996;
56(20):4570‐4574.
50. Garofalo C, Manara MC, Nicoletti G, et al. Efficacy of and resistance
to anti‐IGF‐1R therapies in Ewing’s sarcoma is dependent on insulin
receptor signaling. Oncogene. 2011;30(24):2730‐2740.
51. Mora J, Rodríguez E, de torres C, et al. Activated growth signaling
pathway expression in Ewing sarcoma and clinical outcome. Pediatr
Blood Cancer. 2012;58(4):532‐538.
52. Lin F, Shen Z, Xu X, et al. Evaluation of the expression and role of IGF
pathway biomarkers in human sarcomas. Int J Immunopathol
Pharmacol. 2013;26(1):169‐177.
53. van de Luijtgaarden ACM, Versleijen‐Jonkers YMH, Roeffen MHS,
Schreuder HWB, Flucke UE, van der Graaf WTA. Prognostic and
therapeutic relevance of the IGF pathway in Ewing's sarcoma
patients. Target Oncol. 2013;8(4):253‐260.
54. Zhang H, Zeng X, Li Q, Gaillard‐Kelly M, Wagner CR, Yee D.
Fluorescent tumour imaging of type I IGF receptor in vivo:
comparison of antibody‐conjugated quantum dots and small‐molecule
fluorophore. Br J Cancer. 2009;101(1):71‐79.
55. Park JY, Murakami T, Lee JY, Zhang Y, Hoffman RM, Bouvet M.
Fluorescent‐antibody targeting of insulin‐like growth factor‐1 recep-
tor visualizes metastatic human colon cancer in orthotopic mouse
models. PLoS One. 2016;11(1):e0146504.
56. Macaulay VM, Middleton MR, Protheroe AS, et al. Phase I study of
humanized monoclonal antibody AVE1642 directed against the type
1 insulin‐like growth factor receptor (IGF‐1R), administered in
combination with anticancer therapies to patients with advanced
solid tumors. Ann Oncol. 2013;24(3):784‐791.
57. Sun Y, Sun X, Shen B. Molecular Imaging of IGF‐1R in Cancer. Mol
Imaging. 2017;16:1536012117736648.
58. Smithey BE, Pappo AS, Hill DA. C‐kit expression in pediatric solid
tumors: a comparative immunohistochemical study. Am J Surg Pathol.
2002;26(4):486‐492.
59. Kara IO, Gonlusen G, Sahin B, Ergin M, Erdogan S. A general aspect
on soft‐tissue sarcoma and c‐kit expression in primitive neuroecto-
dermal tumor and Ewing's sarcoma. Is there any role in disease
process? Saudi Med J. 2005;26(8):1190‐1196.
60. Metildi CA, Tang CM, Kaushal S, et al. In vivo fluorescence imaging of
gastrointestinal stromal tumors using fluorophore‐conjugated anti‐
KIT antibody. Ann Surg Oncol. 2013;20(Suppl 3):S693‐S700.
BOSMA ET AL. | 913
61. London CA, Gardner HL, Rippy S, et al. KTN0158, a humanized anti‐
KIT monoclonal antibody, demonstrates biologic activity against both
normal and malignant canine mast cells. Clin Cancer Res. 2017;
23(10):2565‐2574.
62. Leong KG, Karsan A. Recent insights into the role of Notch signaling
in tumorigenesis. Blood. 2006;107(6):2223‐2233.
63. Wang Z, Li Y, Kong D, H. sarkar F. The role of Notch signaling
pathway in epithelial‐mesenchymal transition (EMT) during
development and tumor aggressiveness. Curr Drug Targets. 2010;
11(6):745‐751.
64. Bennani‐Baiti IM, Aryee DN, Ban J, et al. Notch signalling is off and is
uncoupled from HES1 expression in Ewing’s sarcoma. J Pathol.
2011;225(3):353‐363.
65. Petruzzelli L, Takami M, Humes HD. Structure and function of cell
adhesion molecules. Am J Med. 1999;106(4):467‐476.
66. Schuetz AN, Rubin BP, Goldblum JR, et al. Intercellular junctions in
Ewing sarcoma/primitive neuroectodermal tumor: additional evidence of
epithelial differentiation. Mod Pathol. 2005;18(11):1403‐1410.
67. Machado I, López‐Guerrero JA, Navarro S, et al. Epithelial cell
adhesion molecules and epithelial mesenchymal transition (EMT)
markers in Ewing’s sarcoma family of tumors (ESFTs). Do they offer
any prognostic significance? Virchows Arch. 2012;461(3):333‐337.
68. Rabinsky EF, Joshi BP, Pant A, et al. Overexpressed claudin‐1 can be
visualized endoscopically in colonic adenomas in vivo. Cell Mol
Gastroenterol Hepatol. 2016;2(2):222‐237.
69. Colpitts CC, Tawar RG, Mailly L, et al. Humanisation of a claudin‐1‐
specific monoclonal antibody for clinical prevention and cure of HCV
infection without escape. Gut. 2018;67(4):736‐745.
SUPPORTING INFORMATION
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
How to cite this article: Bosma SE, van Driel PB, Hogendoorn
PC, Dijkstra PS, Sier CF. Introducing fluorescence guided
surgery into orthopedic oncology: A systematic review of
candidate protein targets for Ewing sarcoma. J Surg Oncol.
2018;118:906‐914. https://doi.org/10.1002/jso.25224
914 | BOSMA ET AL.
